Rigel files $200 million shelf

New York, Nov. 10 - Rigel Pharmaceuticals, Inc. filed a $200 million shelf registration with the Securities and Exchange Commission.

Included in the S-3 filing are common stock, preferred stock, debt securities, warrants and units. Securities may be structured as convertibles or sold in combination as units.

The South San Francisco, Calif., drug development company working on small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases will use proceeds for research and development and general corporate purposes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.